The follow up of colorectal cancer after curative surgery has to find loco-regional relapses or synchronous metastases, and to detect adenomas and new cancer on the rest of the colon.

The increase of survival after relapse of the colorectal cancer depends on the possibility of curative action or after chemotherapy response.

This is a Phase III open-labeled, multicenter, multidisciplinary, randomised study, comparing 2 arms of 188 patients (i.e. 376 total patients).

Study Period (date of first inclusion/last inclusion): 3 years.

Follow Up: 3 years.

The primary objective is the evaluation of PET performance in the earlier relapse detection of the colorectal cancer relapse in comparison with conventional control (including carcinoembryonic [CEA] levels and other classic radiological exams).

Inclusion Criteria:

• Signed and dated written informed consent
• Confirmed stage II or III (TNM)
• Patient with curative surgery for colorectal adenocarcinoma
• Total digestive endoscopy prior or post surgery.
• Age > 18 years old
• Normal liver ultrasound and chest X-ray or thoraco-abdomino pelvic computed tomography (CT) scan.
• In fertile women, efficient contraception or postmenopausal patient (amenorrhea for at least 1 year)

Exclusion Criteria:

• Serious concomitant pathology
• Uncontrolled diabetes with a classical treatment (glycaemia >1.4 g/l)
• Other malignant tumour within the last 5 years (except for curatively treated basocellular carcinoma of the skin or in situ cervical carcinoma).
• Uncontrolled infection
• Women who are pregnant or lactating
• Inability to understand informed consent
• Psychological or geographic impossibility to follow up for three years.